Alnylam Announces FDA Approval of Supplemental New Drug Appl

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , Jorge Capapey , Kim Hollander , Instagram , Linkedin , Hyperoxaluria Foundation , Global Rare Disease Lead At Alnylam Pharmaceuticals , Drug Administration , Alnylam Pharmaceuticals Inc , Novartis , Exchange Commission , Alnylam Pharmaceuticals , European Medicines Agency , Committee For Medicinal Products Human Use , Primary Hyperoxaluria Type , Lower Urinary , Plasma Oxalate Levels , Adult Patients , Positive Efficacy , Safety Results , Severe Renal Impairment , Including Those , New Drug Application , Vice President , Global Rare Disease Lead , Month Six , Executive Director , Medicinal Products , Human Use , Enhanced Stabilization Chemistry , About Primary Hyperoxaluria Type , Nobel Prize Winning , Private Securities Litigation Reform Act , Quarterly Report , Bend Points , Clinical Trials , Clinj Am Soc ,